Eur J Med Chem
School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chongqing University, Chongqing, 401331, PR China. Electronic address:
Published: July 2018
Herein, triphenylphosphonium cation moieties were incorporated into a dichloroacetophenone derivative, leading to the discovery of novel mitochondria-targeted and tumor-specific pyruvate dehydrogenase kinase 1 (PDK1) inhibitors. Biological studies suggested that all these synthesized compounds had significant in vitro activities, in particular compound 1f, which inhibited PDK1 with an EC value of 0.12 μM, and reduced the proliferation of NCI-H1650 cell with an IC value of 0.21 μM, but showed marginal effect against non-cancerous BEAS-2B cell (IC = 3.28 μM). In addition, 1f decreased the extracellular acidification rate and lactate formation, increased reactive oxygen species production, and depolarized the mitochondrial membrane potential of NCI-H1650 cell, which could serve as a potential modulator to reactive mitochondrial oxidative phosphorylation and reprogram the glucose metabolic pathways in cancer cells. Collectively, these data demonstrated that 1f could be a promising lead for the development of therapeutic PDK1 inhibitor in cancer treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejmech.2018.06.012 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.